Amarin Corp Plc (AMRN)

[oneragman]

HG, I would expect some kind of deal. Maybe Hikma leaves/limits selling into the market with early entry in the RI indication. Is Hikma making a lot of money? Do they have bigger fish to fry? If they are limited on volume, how does that change their cost/benefit analysis for the long term? Also, you could be dealing with a jury trial and that is a wildcard I don't think Hikma would want to face... all imo.
I could be wrong, but I expect the legal arguments to start swinging back towards patent holders. The recent GSK/Teva as well as current SC case heard yesterday, United States v. Arthrex Inc., could very well put patentholder rights to the forefront of the ever changing law.